Cat. No. | Product name | CAS No. |
DC11861 |
TAK-441
A highly potent, orally active hedgehog signaling (Hh) inhibitor with IC50 of 4.4 nM in Gli-luc reporter assays. |
1186231-83-3 |
DC11710 |
GDC-0425
A potent, selective and orally active Chk1 inhibitor. |
1200129-48-1 |
DC11495 |
Allitinib
Allitinib (AST-1306, ALS1306)) is a novel potent, selective irreversible EGFR and HER2 inhibitor with IC50 of 0.5 and 3 nM in cell-free assays. |
897383-62-9 |
DC8618 |
AMG-319
Featured
AMG 319 is an investigational, highly selective, small molecule inhibitor of PI3Kδ that blocks B cell proliferation following BCR stimulation both in vitro and in vivo, inhibits basal AKT phosphorylation, and inhibits proliferation in lymphoid tumor cells |
1608125-21-8 |
DC7360 |
AST-1306
AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases. |
1050500-29-2 |
DC8253 |
AV-412(MP-412)
AV-412(MP-412) is a potent dual inhibitor of EGFR and ErbB2(IC50=19 nM) tyrosine kinases, including the mutant EGFR(L858R IC50=0.51 nM, T790M IC50=0.79 nM); inhibits autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM, respectively. |
451492-95-8 |
DC9309 |
AZD-0156
Featured
AZD-0156 is an orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities. |
1821428-35-6 |
DC9263 |
AZD-3965
Featured
AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit MCT4 at 10 μM. |
1448671-31-5 |
DC7369 |
AZD5438
Featured
AZD5438 is a potent inhibitor of CDK1/2/9 with IC50 of 16 nM/6 nM/20 nM. It is less potent to CDK5/6. |
602306-29-6 |
DC7076 |
AZD-7762
Featured
AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM; equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. |
860352-01-8 |
DC5084 |
AZD-8055
Featured
AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. |
1009298-09-2 |
DC7077 |
AZD8330(ARRY-424704; ARRY-704)
Featured
AZD8330(ARRY-424704; ARRY-704) is a novel, selective, non-ATP competitive MEK 1/2 inhibitor with IC50 of 7 nM. |
869357-68-6 |
DC9939 |
BAY 1082439
BAY 1082439 is a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN. |
1375469-38-7 |
DC10408 |
BAY1125976
Featured
BAY1125976 is a selective allosteric Akt1/2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively. |
1402608-02-9 |
DC9679 |
BAY1217389
Featured
BAY1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. |
1554458-53-5 |
DC8401 |
BI-847325
Featured
BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1. |
1207293-36-4 |
DC8103 |
BLZ-945
Featured
BLZ945 is a highly selective and brain-penetrant inhibitor of CSF1R with IC50 of 1 nM; >3200-fold higher than its affinity for other kinases. |
953769-46-5 |
DC9638 |
BMS-794833
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7/15 nM; also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. |
1174046-72-0 |
DC10609 |
BMS-986158
Featured
BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins. |
1800340-40-2 |
DC10864 |
C188-9
Featured
C188-9 is a potent inhibitor of STAT3 that binds to STAT3 with high affinity (KD=4.7±0.4 nM). C188-9 is well tolerated in mice, shows good oral bioavailability, and is concentrated in tumors. |
432001-19-9 |
DC11709 |
CB-1158
CB-1158 (INCB-01158) is a potent, selective, oral available Arginase inhibitor with IC50 of 98 nM. |
2095732-06-0 |
DC8418 |
CH5183284 (Debio-1347)
Featured
CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1. |
1265229-25-1 |
DC7544 |
CUDC-101
Featured
CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1. |
1012054-59-9 |
DC7810 |
CX-5461
Featured
CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA, has no effect on Pol II, and possesses 250-to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation. |
1138549-36-6 |
DC8404 |
E3330
Featured
E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity. |
136164-66-4 |
DC7128 |
Lucitanib(E3810)
Featured
E-3810 is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity. |
1058137-23-7 |
DC10563 |
E-7046
Featured
E7046 is an orally bioavailable and specific EP4 antagonist, with IC50 of 13.5 nM and Ki of 23.14 nM, exhibiting anti-tumor activities. |
1369489-71-3 |
DC11062 |
E7107
E7107 (E-7107) is a derivative of pladienolide that targets the SF3b subunit of the spliceosome, shows significant antitumor activity in vitro and in vivo. |
630100-90-2 |
DC8489 |
ETC-159
Featured
ETC-159 is a potent and specific inhibitor of Wnt secretion. ETC-159 inhibits _beta_-catenin reporter activity in a dose-dependent manner with an IC50 of 2.9 nM. |
1638250-96-0 |
DC9515 |
PI3K inhibitor GS1059615
GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively. |
958852-01-2 |
DC7141 |
Omipalisib
Featured
GSK2126458 is a highly selective and potent inhibitor of PI3K with Ki of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2 , respectively. |
1086062-66-9 |
DC7812 |
GSK923295
Featured
GSK923295 is a first-in-class, specific allosteric inhibitor of CENP-E kinesin motor ATPase with Ki of 3.2 nM, and less potent to mutant I182 and T183. |
1088965-37-0 |
DC8768 |
HMN-214
Featured
HMN-214(IVX214) is a potent PLK1 inhibitor an average IC50 of 0.12 μM. |
173529-46-9 |
DC11303 |
CT7001 hydrochloride
Featured
ICEC0942 is a selective CDK7 inhibitor, with IC50s of 41 nM and 578 nM for CDK7/CycH/MAT1 and CDK2/cycE1, respectively. |
1805789-54-1 |
DC10918 |
INCB053914
INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively. |
1620012-39-6 |
DC9829 |
IPI-549
Featured
IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. |
1693758-51-8 |
DC7177 |
JNJ 38877605
Featured
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. |
943540-75-8 |
DC10487 |
KO947
Featured
KO-947 is a small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2), as a potential treatment for cancers in which the mitogen activated protein kinase (MAPK) pathway. |
1695533-89-1 |
DC9788 |
KP1019(FFC14A)
KP1019 (FFC14A) is just the second ruthenium-based anticancer agent after NAMI-A which was developed to the stage of clinical trials. |
124875-20-3 |
DC10454 |
KRN633
Featured
KRN633 is a potent and selective VEGFR inhibitor. which inhibits tyrosine phosphorylation of VEGFR-2 (IC50 = 1.16 nmol/L) in human umbilical vein endothelial cells. |
286370-15-8 |
DC8023 |
KX2-391
Featured
KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. |
897016-82-9 |
DC7943 |
LYS6K2(LY2584702) tosylate salt
Featured
LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes. |
1082949-68-5 |
DC10675 |
LY3200882
Featured
LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor. |
1898283-02-7 |
DC12261 |
LY3295668 (AK-01)
LY3295668 is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively. |
1919888-06-4 |
DC8479 |
MK-2461
MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. |
917879-39-1 |
DC7466 |
MK-5108
MK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM; 220- and 190-fold more selective for Aurora A than Aurora B/C. |
1010085-13-8 |
DC9365 |
MLN8054
Featured
MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM; exhibits more than 40-fold selective for Aurora A than Aurora B. |
869363-13-3 |
DC7202 |
MPC-3100
MPC-3100 is an orally bioavailable, synthetic, second-generation small-molecule inhibitor of heat shock protein 90 (Hsp90) with potential antineoplastic activity. |
958025-66-6 |
DC10951 |
MPT0E028
MPT0E028 is a potent HDAC inhibitor that inhibits nuclear HDAC activity with IC50 of 11.1 nM in HeLa cells, 9-30 times more potent than SAHA. |
1338320-94-7 |
DC9787 |
NAMI-A
NAMI-A is a ruthenium anticancer agent and a metastasis inhibitor. |
201653-76-1 |
DC3133 |
NVP-BGT226 (BGT226)
Featured
NVP-BGT226 is a novel dual PI3K/mTOR inhibitor with IC50 of 1 nM. |
1245537-68-1 |
DC7219 |
OSI 930
Featured
OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl. |
728033-96-3 |
DC8259 |
PF0477736
Featured
PF 477736 is a CHK inhitor with Ki values of 0.49 and 47 nM for Chk1 and Chk2 respectively. A proprietary compound targeting cell cycle checkpoint kinase 1 (chk1) with potential chemopotentiation activity |
952021-60-2 |
DC3168 |
PF-562271 PHSO3H SALT
Featured
PF-00562271 is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively. |
939791-38-5 |
DC7059 |
PF-03758309
Featured
PF-03758309 is an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity. |
898044-15-0 |
DC7081 |
PF-04217903
Featured
PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant). |
956905-27-4 |
DC3169 |
PF-562271
Featured
PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK and Pyk2 with IC50 of 1.5 nM and 14 nM, respectively. |
717907-75-0 |
DC10451 |
PFK158
Featured
PFK-158 is a potent and selective inhibitor of PFKFB3 that is currently being investigated in a phase I study in patients with advanced solid malignancies. |
1462249-75-7 |
DC10641 |
PRN1371
Featured
PRN1371 is an irreversible covalent FGFR1-4 kinase inhibitor, with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, 2, 3, 4 and CSF1R, respectively. |
1802929-43-6 |
DC2068 |
R547
R547 is a potent and selective CDK inhibitor with Ki and IC50 of 1-3 nM and 80 nM respectively. |
741713-40-6 |
DC10463 |
Repotrectinib(TPX-005)
Featured
Repotrectinib(TPX-005) is a multi-target macrocycle inhibitor of anaplastic lymphoma kinase (ALK), c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1), and neurotrophic tyrosine kinase receptor (TRK) |
1802220-02-5 |
DC7489 |
RO5126766(CH5126766)
RO5126766(CH5126766) is a Raf/MEK dual kinase inhibitor. |
946128-88-7 |
DC7290 |
Semaxanib (SU5416)
Featured
Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor with IC50 of 1.23 μM, 20-fold more selective for VEGFR than PDGFRβ, lack of activity against EGFR, InsR and FGFR. |
204005-46-9 |
DC7294 |
SGX-523
Featured
SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. |
1022150-57-7 |
DC11633 |
TAK-243
Featured
TAK-243 (MLN-7243, AOB87172) is a small-molecule, cell-permeable inhibitor of ubiquitin-activating enzyme E1 (UAE1). |
1450833-55-2 |
DC7308 |
TAK-733
Featured
TAK-733 is a potent and selective MEK allosteric site inhibitor for MEK1 with IC50 of 3.2 nM, inactive to Abl1, AKT3, c-RAF, CamK1, CDK2, c-Met, etc. |
1035555-63-5 |
DC8739 |
Talabostat mesylate
Talabostat mesilate(PT-100; Val-boroPro) is an orally active, specific inhibitor of dipeptidyl peptidases(IC50=1 nM for DPP4), including tumor-associated fibroblast activation protein. |
150080-09-4 |
DC8223 |
TP-0903
Featured
TP-0903 is a a high-affinity Axl inhibitor with IC50 of 27 nM. |
1341200-45-0 |
DC8884 |
Voxtalisib (XL765, SAR245409)
Featured
Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. |
934493-76-2 |
DC1077 |
ZSTK474
Featured
ZSTK474 is a potent pan-class I PI3K inhibitor with IC50 of 37 nM. |
475110-96-4 |
DC10764 |
Theliatinib (HMPL-309)
Featured
Theliatinib (HMPL-309) is a novel small molecule, EGFR tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenesis activities. |
1353644-70-8 |
DC10034 |
GLPG0187
Featured
GLPG0187 is a small molecule integrin receptor antagonist (IRA) with potential antineoplastic activity. |
1320346-97-1 |
DC11089 |
TAS-120 (Futibatinib)
Featured
TAS-120 is a highly potent and selective irreversible FGFR inhibitor, effective in tumors harboring various FGFR gene abnormalities. |
1448169-71-8 |
DC7622 |
BIBX1382
Featured
BIBX 1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 μM) and a range of other related tyrosine kinases (IC50 > 10 μM). |
196612-93-8 |
DC7488 |
RO4987655
Featured
RO4987655(CH-4987655) is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1/MEK1 IC50=5.2 nM), with potential antineoplastic activity. |
874101-00-5 |